Document Detail


Pilot study of fluzinamide (N-methyl-3-[3-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide) in refractory partial seizures.
MedLine Citation:
PMID:  4022365     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We conducted a pilot study of fluzinamide in 15 adults with refractory partial seizures. After a baseline period, fluzinamide was added to the existing regimen of phenytoin and carbamazepine and increased to maximum tolerated dose. Common side effects included dizziness, diplopia, ataxia, headache, nausea, and rash, resulting in patient withdrawal in six cases. Seizures became less frequent in four of the nine patients who completed the 8-week trial.
Authors:
P D Donofrio; C Sackellares; J A Madsen; F Matsuo; B Abou-Khalil; S Berent; J Wagner; S B Ater; H Mavor; P E Gay
Related Documents :
8364265 - Evaluation of plasmapheresis in the treatment of an acute overdose of carbamazepine.
7140665 - Anticonvulsant drugs and cognitive functions.
19786695 - Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study.
18424075 - Long-term outcome of gamma-knife surgery in temporal lobe epilepsy.
7411345 - Technical aspects in the management of the meconium aspiration syndrome with extracorpo...
7695115 - Colonization of mechanical ventilation bags during use.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Neurology     Volume:  35     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1985 Aug 
Date Detail:
Created Date:  1985-09-05     Completed Date:  1985-09-05     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1239-41     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anticonvulsants / therapeutic use
Azetidines / administration & dosage,  adverse effects,  therapeutic use*
Azetines / therapeutic use*
Central Nervous System Diseases / chemically induced
Drug Resistance
Gastrointestinal Diseases / chemically induced
Humans
Liver Function Tests
Male
Middle Aged
Pilot Projects
Seizures / classification,  drug therapy*,  physiopathology
Skin Diseases / chemically induced
Grant Support
ID/Acronym/Agency:
M01RR00042/RR/NCRR NIH HHS; N01-NS-1-2363/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Azetidines; 0/Azetines; 76263-13-3/fluzinamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatic and encephalopathic components of Reye's syndrome: factor analysis of admission data from 20...
Next Document:  Usefulness of computed tomography in predicting outcome after aneurysmal subarachnoid hemorrhage: a ...